Stephens analyst Chris Cooley reiterated a Buy rating on Glaukos (NYSE: GKOS) today and set a price target of $50. The company’s shares opened today at $41.01.
According to TipRanks.com, Cooley is a 5-star analyst with an average return of 36.6% and a 76.3% success rate. Cooley covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp, Staar Surgical Company, and DENTSPLY SIRONA Inc.
Glaukos has an analyst consensus of Moderate Buy, with a price target consensus of $44, which is a 7.3% upside from current levels. In a report released today, Piper Jaffray also maintained a Buy rating on the stock with a $46 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $46.50 and a one-year low of $23.08. Currently, Glaukos has an average volume of 422.6K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Glaukos Corp. is an ophthalmic medical device company, which engages in the development and commercialization of surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. Its Micro Invasive Glaucoma Surgery procedures are designed to reduce intraocular eye pressure by improving aqueous outflow through the natural physiologic pathway.
